BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Alliance Pharmaceutical Corp. (ALLP) And Beijing Double-Crane Pharmaceutical Co., Ltd. Announce A Memorandum Of Understanding Concerning The Development, Licensing And Marketing Of Oxygent(tm) In The People's Republic Of China


10/19/2005 5:13:14 PM

SAN DIEGO, April 5 /PRNewswire-FirstCall/ -- Alliance Pharmaceutical Corp. ("Alliance") (BULLETIN BOARD: ALLP) , through its subsidiary PFC Therapeutics, LLC, and Beijing Double-Crane Pharmaceutical Co., Ltd. ("Double-Crane"), today announced that they have entered into a Memorandum of Understanding ("MOU") for the development of Oxygent(tm) in The People's Republic of China ("PRC"). Pursuant to the MOU, the parties intend to negotiate a final license agreement whereby Double-Crane will be granted the right to develop and commercialize Oxygent in the PRC. The parties contemplate that Double-Crane will make an upfront license fee payment and will be obligated to make milestone and royalty payments to Alliance under certain circumstances. In addition, Double-Crane will be responsible for conducting clinical trials in the PRC necessary to receive marketing approval for Oxygent and that Alliance will have the right to use any data derived from these clinical trials in other territories. Alliance and Double-Crane have also agreed to discuss the possibility of manufacturing Oxygent in the PRC for distribution worldwide. The parties have agreed to negotiate exclusively with one another in good faith for the purpose of entering into a definitive license agreement with respect to the subject matter of the MOU by May 15, 2005.

About Double-Crane

Double-Crane was established and listed on May 22, 1997 (share code: 600062) in the Shanghai Securities Exchange China. By the end of 2004, Double-Crane had controlled shareholding in 23 subsidiaries and shares in seven companies in ten provinces throughout China. Double-Crane covers many areas of R&D, production, marketing, logistics and equipment, etc., and participates in markets like synthetic antibiotics, cardiovascular, raw materials and GI. Double-Crane is the market leader in China for IV solutions. The revenues of Double-Crane in 2004 were around RMB 4.2 billion (equals to US$ 510 million). Double-Crane is one of the largest pharmaceutical companies in China.

About Alliance

Alliance Pharmaceutical Corp., founded in 1989, is a development-stage pharmaceutical company that is currently focused on developing its lead product, Oxygent(tm). Alliance is currently the only company that has advanced a synthetic PFC emulsion-based oxygen therapeutic into late-stage multi-center international clinical trials in both Europe and North America. Alliance is developing Oxygent as an intravascular oxygen therapeutic, based on its proprietary PFC and surfactant technologies.

Except for historical information, the matters set forth in this release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth herein, including the results of further negotiations with Double-Crane, the results of scientific advice of the regulatory authorities of the PRC and the uncertainties associated with the conduct of preclinical or clinical studies. Alliance refers you to cautionary information contained in documents Alliance files with the Securities and Exchange Commission from time to time, including the last Form 10-KSB and Form 10-QSB, and those risk factors set forth in the most recent registration statement on Form SB-2 (File No. 333-119428). Alliance is under no obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

Alliance Pharmaceutical Corp.

CONTACT: Corporate Communications, Alliance Pharmaceutical Corp.,+1-858-410-5275



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES